published meta-analysis   sensitivity analysis   studies

sarilumab high dose (400mg) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80] 0.86[0.46; 1.60]Lescure (Sarilumab 400mg), 2021, sarilumab phase 2 high dose, 020%389seriousnot evaluable clinical improvementdetailed resultssarilumab phase 2 high dose, 0 2.09 [1.00; 4.36] 2.09[1.00; 4.36]sarilumab phase 2 high dose, 010%132NAnot evaluable death or ventilationdetailed resultssarilumab phase 2 high dose, 0 0.39 [0.18; 0.82] 0.39[0.18; 0.82]sarilumab phase 2 high dose, 010%132NAnot evaluable mechanical ventilationdetailed resultssarilumab phase 2 high dose, 0 0.27 [0.10; 0.71] 0.27[0.10; 0.71]sarilumab phase 2 high dose, 010%132NAnot evaluable off oxygenationdetailed resultssarilumab phase 2 high dose, 0 1.99 [0.95; 4.15] 1.99[0.95; 4.15]sarilumab phase 2 high dose, 010%132NAnot evaluable serious adverse eventsdetailed resultsLescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] 1.38[0.76; 2.51]Lescure (Sarilumab 400mg), 202110%259NAnot evaluable adverse eventsdetailed resultsLescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] 1.31[0.76; 2.27]Lescure (Sarilumab 400mg), 202110%259NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-29 08:02 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 646 - roots T: 290